22nd Century Group Q3 2026 Earnings Date & Estimates

22nd Century Group (NASDAQ:XXII). is a biotechnology and tobacco company focused on developing products with reduced nicotine content. Its technology is designed to alter the nicotine levels in tobacco plants, with the goal of supporting smoking cessation and reducing exposure to nicotine among adult smokers.

The company’s best-known products include VLN cigarettes, which contain substantially less nicotine than conventional cigarettes. VLN received authorization from the U.S. Food and Drug Administration to be marketed as a modified-risk tobacco product. 22nd Century has also developed research cigarettes and other reduced-nicotine tobacco products for use in clinical and public-health studies.

Historically based in Buffalo, New York, 22nd Century Group served the U.S. tobacco and research markets and pursued opportunities involving tobacco harm reduction, smoking cessation and reduced-nicotine products. The company has also explored applications of its plant-engineering technology in cannabis and hemp. Its operations and product strategy have changed over time, so current product availability and corporate leadership should be verified through the company’s latest public filings.